KR860008289A - Protein evaporation method - Google Patents

Protein evaporation method Download PDF

Info

Publication number
KR860008289A
KR860008289A KR1019860003320A KR860003320A KR860008289A KR 860008289 A KR860008289 A KR 860008289A KR 1019860003320 A KR1019860003320 A KR 1019860003320A KR 860003320 A KR860003320 A KR 860003320A KR 860008289 A KR860008289 A KR 860008289A
Authority
KR
South Korea
Prior art keywords
protein
ion source
promoter
manganese
interferon
Prior art date
Application number
KR1019860003320A
Other languages
Korean (ko)
Other versions
KR940011533B1 (en
Inventor
가즈아끼 기따노
시게루 후지모또
Original Assignee
다께다 야꾸힝 고오교 가부시끼가이샤
구라바야시 이꾸시로
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP1985/000248 external-priority patent/WO1986006410A1/en
Application filed by 다께다 야꾸힝 고오교 가부시끼가이샤, 구라바야시 이꾸시로 filed Critical 다께다 야꾸힝 고오교 가부시끼가이샤
Publication of KR860008289A publication Critical patent/KR860008289A/en
Application granted granted Critical
Publication of KR940011533B1 publication Critical patent/KR940011533B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음No content

Description

단백질의 증수법(增收法)Protein evaporation method

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 인체 IL-2의 아미노산 서열을 나타낸다.1 shows the amino acid sequence of human IL-2.

제5도 및 6도는 각각 참고예에 설명된 플라스미드 pTF 1 및 pTB 285의 제조단계를 나타낸다.5 and 6 show the preparation steps of the plasmids pTF 1 and pTB 285 described in the reference examples, respectively.

Claims (21)

N-말단에 해독 출발코오돈 ATG에 해당하는 메티오닌을 함유하지 않는 단백질의 수율을 증가시키기 위하여, (1) 철이온원, 망간이온원 또는 그의 흔합물 및 (2) 천연질소원을 포함하는 배지 내에서 해독 출발 코오돈의 하류에 단백질의 구조 유전자를 포함하는 형질전환벡터를 갖는 에스케리키아 콜리를 배양함을 특징으로 하는 단백질의 증수법.In order to increase the yield of the protein containing no methionine corresponding to the detoxification start codon ATG at the N-terminus, in a medium comprising (1) an iron ion source, a manganese ion source or a combination thereof and (2) a natural nitrogen source A method for multiplying a protein characterized by culturing Escherichia coli having a transformation vector comprising a structural gene of a protein downstream of a translational start codon. 제1항에 있어서, 단백질이 시토킨, 형질전환 성장인자, 펩티드 단백질 호르몬, 병원성 미생물의 항원 단백질, 효소 및 혈청 단백질로 구성된 군으로부터 선택된 생리적으로 활성인 단백질임을 특징으로 하는 방법.The method of claim 1, wherein the protein is a physiologically active protein selected from the group consisting of cytokines, transforming growth factors, peptide protein hormones, antigenic proteins of pathogenic microorganisms, enzymes and serum proteins. 제2항에 있어서, 시토킨이 인터페론 또는 인터로이킨임을 특징으로 하는 방법.The method of claim 2, wherein the cytokine is interferon or interleukin. 제3항에 있어서, 인터페론이 인터페론-α 또는 인터페론-β임을 특징으로 하는 방법.The method of claim 3, wherein the interferon is interferon-α or interferon-β. 제3항에 있어서, 인터로이킨이 인터로이킨-2임을 특징으로 하는 방법.4. The method of claim 3 wherein the interleukin is interleukin-2. 제1항에 있어서, 형질 전환벡터가 프로모터를 함유함을 특징으로 하는 방법.The method of claim 1, wherein the transformation vector contains a promoter. 제6항에 있어서, 프로모터가 λPL프로모터임을 특징으로 하는 방법.7. The method of claim 6, wherein the promoter is a λ PL promoter. 제6항에 있어서, 프로모터가 트립토판 프로모터임을 특징으로 하는 방법.7. The method of claim 6, wherein the promoter is a tryptophan promoter. 제1항에 있어서, 철이온원이 이온염임을 특징으로 하는 방법.The method of claim 1 wherein the iron ion source is an ionic salt. 제9항에 있어서, 이온 염이 3가 철의 무기산염임을 특징으로 하는 방법.10. The process of claim 9, wherein the ionic salt is an inorganic acid salt of trivalent iron. 제1항에 있어서, 망간 이온원이 망간염임을 특징으로 하는 방법.The method of claim 1 wherein the manganese ion source is manganese. 제11항에 있어서, 망간염이 무기산염임을 특징으로 하는 방법.The method of claim 11, wherein the manganese salt is an inorganic acid salt. 제1항에 있어서, 배지가 10-6-10-3몰농도의 칠이온원을 함유함을 특징으로 하는 방법.2. The method of claim 1, wherein the medium contains a chilled ion source at a molar concentration of 10 -6 -10 -3 . 제1항에 있어서, 배지가 10-6-10-3몰농도의 망간이온원을 함유함을 특징으로 하는 방법.The method of claim 1 wherein the medium contains a manganese ion source at a molar concentration of 10 −6 −10 −3 . 제1항에 있어서, 배지가 총 106-10-3몰농도의 철이온원 및 망간 이온원의 혼합물을 함유함을 특징으로 하는 방법.The method of claim 1 wherein the medium contains a mixture of iron and manganese ion sources in a total of 10 6 -10 -3 molar concentrations. 제1항에 있어서, 천연 질소원이 카사미노산, 펩톤, 효모 추출액 및 맥아 추출액으로 구성된 군으로부터 선택된 것임을 특징으로 하는 방법.The method of claim 1 wherein the natural nitrogen source is selected from the group consisting of casamino acid, peptone, yeast extract and malt extract. 제16항에 있어서. 질소원이 카사미노산임을 특징으로 하는 방법.The method of claim 16. Characterized in that the nitrogen source is casamino acid. 제1항에 있어서, 배지가 Ig/ℓ-50g/ℓ농도의 질소원을 함유함을 특징으로 하는 방법.The method of claim 1 wherein the medium contains a nitrogen source at an Ig / L-50 g / L concentration. 제1항에 있어서, 배양을 산성조건하에 실시함을 특징으로 하는 방법.The method of claim 1, wherein the culture is carried out under acidic conditions. 제7항에 있어서, 배양을 증식중에는 25-35℃에서 실시하고 그 추에 42℃ 근처로 변화시켜 실시함을 특징으로 하는 방법.8. The method of claim 7, wherein the culturing is carried out at 25-35 ° C. during propagation and by changing the weight to near 42 ° C. 제8항에 있어서, 성장의 중간 단계까지는 37℃ 근처의 온도를 유지한채 성장을 실시하고 그 후에는 증식상태에 비례하여 20-30℃로 낮춤을 특징으로 하는 방법.The method of claim 8, wherein the growth is carried out at a temperature near 37 ° C. until the intermediate stage of growth and thereafter lowered to 20-30 ° C. in proportion to the growth state. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019860003320A 1985-04-30 1986-04-29 Method of producing protein KR940011533B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JPPCT/JP85/00248 1985-04-30
MCPCT/JP85/248 1985-04-30
PCT/JP1985/000248 WO1986006410A1 (en) 1985-04-30 1985-04-30 Process for increasing yield of interleukin-2
JP22151785 1985-10-03
JP221517/1985 1985-10-03
JP61045667A JPH0634746B2 (en) 1985-04-30 1986-03-03 Interleukin Revenue Increase Method
JP45667/1986 1986-03-03

Publications (2)

Publication Number Publication Date
KR860008289A true KR860008289A (en) 1986-11-14
KR940011533B1 KR940011533B1 (en) 1994-12-20

Family

ID=26425978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860003320A KR940011533B1 (en) 1985-04-30 1986-04-29 Method of producing protein

Country Status (2)

Country Link
JP (1) JPH0634746B2 (en)
KR (1) KR940011533B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6443185A (en) * 1987-08-12 1989-02-15 Toray Industries Culture medium for propagation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria

Also Published As

Publication number Publication date
JPS62175191A (en) 1987-07-31
KR940011533B1 (en) 1994-12-20
JPH0634746B2 (en) 1994-05-11

Similar Documents

Publication Publication Date Title
EP0156354B1 (en) Controlled oxidation of microbially produced cysteine containing proteins
US4656132A (en) Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
ES8604252A1 (en) Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods.
DK122686D0 (en) PREPARATION OF PROTEINS
DE3588249D1 (en) Method of producing human growth hormones
KR870006188A (en) Method for preparing granulocyte macrophage colony promoter factor (GM-CSF) protein
Kitano et al. Intracellular degradation of recombinant proteins in relation to their location in Escherichia coli cells
KR870000428A (en) Method of manufacturing human serum albumin
US4894334A (en) Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
EP0210846A2 (en) Method for extracting protein with organic acid
Schiller et al. UDP-glucose dehydrogenase from Escherichia coli: purification and subunit structure
KR860008289A (en) Protein evaporation method
Emerick et al. Expression of a β-lactamase preproinsulin fusion protein in Escherichia coli
EP0152483B1 (en) Process for producing peptide
AU603545B2 (en) Media for increased yield of protein free of N-terminal methionine from recombinant escherichia coli
DE3671243D1 (en) METHOD FOR THE MICROBIOLOGICAL PRODUCTION OF HUMAN SERUM ALBUMIN.
JPS6420086A (en) Polypeptide and production thereof
DE3889562D1 (en) Recombinant plasmids that can be used to express heterologous proteins in Bacillus.
Mackay et al. Molecular structure of exonuclease I from Escherichia coli B
ES8801948A1 (en) Envelope protein of acquired immune deficiency syndrome virus
JPH03108495A (en) Activator, activator gene and marker gene and production of useful and physiologically active substance

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031205

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee